Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

David J. Pinato; Antonio D’Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesús Miguéns Blanco; Caroline Ward; Charalampos‐Vlasios Stikas; Mark R. Openshaw; Nicole Acuti; Georgios Nteliopoulos; Cristina Balcells; Hector C. Keun; Robert Goldin; Paul J. Ross; Alessio Cortellini; Robert Thomas; Anna-Mary Young; Nathan Danckert; Paul Tait; Julian R. Marchesi; Bertram Bengsch; Rohini Sharma

doi:10.1158/1078-0432.25956664.v1

Abstract

Supplementary Figure S10. Bar graphs showing the absence of association between entropy and response prior to the start of pembrolizumab (A) and at the end of treatment (B). Abbreviations: ICI, immune checkpoint inhibitor; ns, not significant; EOT, end of treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pinato et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3e21 https://doi.org/10.1158/1078-0432.25956664.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

Abstract

Discussion

Cite This Study

Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading